File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Capecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer

TitleCapecitabine monotherapy for recurrent and metastatic nasopharyngeal cancer
Authors
KeywordsCapecitabine
Hand-foot syndrome
Nasopharyngeal carcinoma
Palliative chemotherapy
Issue Date2008
PublisherOxford University Press. The Journal's web site is located at http://jjco.oxfordjournals.org/
Citation
Japanese Journal Of Clinical Oncology, 2008, v. 38 n. 4, p. 244-249 How to Cite?
Abstract
background: Capecitabine monotherapy had activity in recurrent/metastatic nasopharyngeal carcinoma (NPC) as demonstrated previously in a small pilot study. We conducted a retrospective review of patients who received capecitabine for recurrent and metastatic NPC to further evaluate its clinical benefits. Methods: Forty-nine patients with recurrent and metastatic NPC received capecitabine at a dose of 1-1.25 G/m2 twice daily for 14 days in 3-week cycles. Disease sites were locoregional in 29%, distant in 45% and locoregional plus distant in 26%. All except one had prior platinum-based chemotherapy for relapse or as adjunctive treatment. Median follow-up was 10 months (range: 3-41). Results: Treatment was generally well tolerated. Hand-foot syndrome was common and occurred in 86%; (25% Grade 3). Grade 3 hematological toxicity occurred in 6%. Partial response rate was 31% (95% CI: 18%, 44%) and complete response rate was 6% (95% CI: 0%, 13%), for an overall response rate of 37% (95% CI: 23%, 50%). Median time-to-progression was 5 months and median survival was 14 months. One- and two-year survival rates were 54 and 26%, respectively. Significantly better survival was observed in patients treated for locoregional recurrence and those with severe hand-foot syndrome. Conclusions: Capecitabine has single agent activity in NPC and severe hand-foot syndrome predicts favorable outcome. Based on our experience, capecitabine monotherapy should be considered in patients with recurrent/ metastatic NPC. © The Author (2008). Published by Oxford University Press. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/83489
ISSN
2013 Impact Factor: 1.747
ISI Accession Number ID
References

 

Author Affiliations
  1. The University of Hong Kong
  2. Queen Mary Hospital Hong Kong
DC FieldValueLanguage
dc.contributor.authorChua, Den_HK
dc.contributor.authorWei, WIen_HK
dc.contributor.authorSham, JSTen_HK
dc.contributor.authorAu, GKHen_HK
dc.date.accessioned2010-09-06T08:41:39Z-
dc.date.available2010-09-06T08:41:39Z-
dc.date.issued2008en_HK
dc.identifier.citationJapanese Journal Of Clinical Oncology, 2008, v. 38 n. 4, p. 244-249en_HK
dc.identifier.issn0368-2811en_HK
dc.identifier.urihttp://hdl.handle.net/10722/83489-
dc.description.abstractbackground: Capecitabine monotherapy had activity in recurrent/metastatic nasopharyngeal carcinoma (NPC) as demonstrated previously in a small pilot study. We conducted a retrospective review of patients who received capecitabine for recurrent and metastatic NPC to further evaluate its clinical benefits. Methods: Forty-nine patients with recurrent and metastatic NPC received capecitabine at a dose of 1-1.25 G/m2 twice daily for 14 days in 3-week cycles. Disease sites were locoregional in 29%, distant in 45% and locoregional plus distant in 26%. All except one had prior platinum-based chemotherapy for relapse or as adjunctive treatment. Median follow-up was 10 months (range: 3-41). Results: Treatment was generally well tolerated. Hand-foot syndrome was common and occurred in 86%; (25% Grade 3). Grade 3 hematological toxicity occurred in 6%. Partial response rate was 31% (95% CI: 18%, 44%) and complete response rate was 6% (95% CI: 0%, 13%), for an overall response rate of 37% (95% CI: 23%, 50%). Median time-to-progression was 5 months and median survival was 14 months. One- and two-year survival rates were 54 and 26%, respectively. Significantly better survival was observed in patients treated for locoregional recurrence and those with severe hand-foot syndrome. Conclusions: Capecitabine has single agent activity in NPC and severe hand-foot syndrome predicts favorable outcome. Based on our experience, capecitabine monotherapy should be considered in patients with recurrent/ metastatic NPC. © The Author (2008). Published by Oxford University Press. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://jjco.oxfordjournals.org/en_HK
dc.relation.ispartofJapanese Journal of Clinical Oncologyen_HK
dc.rightsJapanese Journal of Clinical Oncology. Copyright © Oxford University Press.en_HK
dc.subjectCapecitabineen_HK
dc.subjectHand-foot syndromeen_HK
dc.subjectNasopharyngeal carcinomaen_HK
dc.subjectPalliative chemotherapyen_HK
dc.titleCapecitabine monotherapy for recurrent and metastatic nasopharyngeal canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0368-2811&volume=38&spage=244&epage=9&date=2008&atitle=Capecitabine+monotherapy+for+recurrent+and+metastatic+nasopharyngeal+cancer.en_HK
dc.identifier.emailChua, D: dttchua@hkucc.hku.hken_HK
dc.identifier.emailWei, WI: hrmswwi@hku.hken_HK
dc.identifier.authorityChua, D=rp00415en_HK
dc.identifier.authorityWei, WI=rp00323en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/jjco/hyn022en_HK
dc.identifier.pmid18407933en_HK
dc.identifier.scopuseid_2-s2.0-42549151234en_HK
dc.identifier.hkuros141513en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-42549151234&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume38en_HK
dc.identifier.issue4en_HK
dc.identifier.spage244en_HK
dc.identifier.epage249en_HK
dc.identifier.isiWOS:000255439200002-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridChua, D=7006773480en_HK
dc.identifier.scopusauthoridWei, WI=7403321552en_HK
dc.identifier.scopusauthoridSham, JST=7101655565en_HK
dc.identifier.scopusauthoridAu, GKH=7003748615en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats